These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Heon S; Yeap BY; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE Clin Cancer Res; 2010 Dec; 16(23):5873-82. PubMed ID: 21030498 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer. Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450 [TBL] [Abstract][Full Text] [Related]
7. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536 [TBL] [Abstract][Full Text] [Related]
8. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer. Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909 [TBL] [Abstract][Full Text] [Related]
10. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564 [TBL] [Abstract][Full Text] [Related]
11. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced Ortega-Granados AL; Artal-Cortes Á; Aguiar-Bujanda D; Oramas J; Fírvida JL; DE Castro J; Fuentes JC; Gordo R; Galán R; Trigo J; Anticancer Res; 2019 Mar; 39(3):1317-1328. PubMed ID: 30842164 [TBL] [Abstract][Full Text] [Related]
12. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Weickhardt AJ; Scheier B; Burke JM; Gan G; Lu X; Bunn PA; Aisner DL; Gaspar LE; Kavanagh BD; Doebele RC; Camidge DR J Thorac Oncol; 2012 Dec; 7(12):1807-1814. PubMed ID: 23154552 [TBL] [Abstract][Full Text] [Related]
13. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Pennell NA; Neal JW; Chaft JE; Azzoli CG; Jänne PA; Govindan R; Evans TL; Costa DB; Wakelee HA; Heist RS; Shapiro MA; Muzikansky A; Murthy S; Lanuti M; Rusch VW; Kris MG; Sequist LV J Clin Oncol; 2019 Jan; 37(2):97-104. PubMed ID: 30444685 [TBL] [Abstract][Full Text] [Related]
14. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835 [TBL] [Abstract][Full Text] [Related]
15. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. Park K; Yu CJ; Kim SW; Lin MC; Sriuranpong V; Tsai CM; Lee JS; Kang JH; Chan KC; Perez-Moreno P; Button P; Ahn MJ; Mok T JAMA Oncol; 2016 Mar; 2(3):305-12. PubMed ID: 26720423 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Sekine A; Satoh H; Iwasawa T; Tamura K; Hayashihara K; Saito T; Kato T; Arai M; Okudela K; Ohashi K; Ogura T Med Oncol; 2014 Oct; 31(10):228. PubMed ID: 25208818 [TBL] [Abstract][Full Text] [Related]
18. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835 [TBL] [Abstract][Full Text] [Related]
19. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627 [TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Zhou Q; Xu CR; Cheng Y; Liu YP; Chen GY; Cui JW; Yang N; Song Y; Li XL; Lu S; Zhou JY; Ma ZY; Yu SY; Huang C; Shu YQ; Wang Z; Yang JJ; Tu HY; Zhong WZ; Wu YL Cancer Cell; 2021 Sep; 39(9):1279-1291.e3. PubMed ID: 34388377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]